Monopar Therapeutics (NASDAQ:MNPR) rose 19.09% on June 23, 2026, as institutional event raised visibility for the rare-disease pipeline, with shares closing at $81.77.

Key Highlights

  • Rose 19.09%: Monopar Therapeutics closed at $81.77 on June 23 after moving $13.11 per share.
  • Catalyst: During the session, institutional event raised visibility for the rare-disease pipeline.
  • Company: Monopar Therapeutics develops medicines for oncology and rare diseases.
  • Session: The stock finished at $81.77, while the available company record showed a disclosed catalyst for the move.

Monopar Therapeutics (NASDAQ:MNPR) rose 19.09% on June 23, 2026, closing at $81.77 after a $13.11 per-share move. The session’s advance came as institutional event raised visibility for the rare-disease pipeline, based on the available company disclosures and trading context.

The company held a virtual investor meeting hosted by a major investment bank, increasing institutional visibility around its Wilson's disease pipeline candidate, MNPR-101, an anti-uPAR antibody. Investors positioned ahead of anticipated clinical programme milestones.

Monopar Therapeutics develops medicines for oncology and rare diseases.

Monopar is a clinical-stage oncology and rare disease company. The gain was substantial in percentage terms but occurred on relatively thin volume, amplifying the move.

The update concerned the development or regulatory path of a healthcare programme rather than a completed commercial launch. Clinical-stage milestones can include agency feedback, trial design, patient data or filing plans, each of which carries a different level of regulatory significance.

The shares closed at $81.77 after the market incorporated the disclosed programme information. The available record showed no additional approval decision during the June 23 session unless specifically stated in the company update.

For the June 23 close, the defining facts were the 19.09% advance, the $81.77 closing price and the catalyst described above. Any further change in the investment record would require a new filing, financial update, regulatory communication or transaction announcement from the company.